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Abstract 
Background: Acute and transient psychotic disorders (ATPD) are characterized by an acute onset and a 
remitting course, and overlap with subgroups of the clinical high-risk state for psychosis. The long-term course 
and outcomes of ATPD are not completely clear.  
Methods: Electronic health record-based retrospective cohort study, including all patients who received a first 
index diagnosis of ATPD (F23, ICD-10) within the South London and Maudsley (SLaM) National Health 
Service Trust, between 1st April 2006 and 15th June 2017. The primary outcome was risk of developing 
persistent psychotic disorders, defined as the development of any ICD-10 diagnoses of non-organic psychotic 
disorders. Cumulative risk of psychosis onset was estimated through Kaplan-Meier failure functions (non-
competing risks) and Greenwood confidence intervals. 
Results: A total of 3074 patients receiving a first index diagnosis of ATPD (F23, ICD-10) within SLaM were 
included. The mean follow-up was 1495 days. After 8-year, 1883 cases (61.26%) retained the index diagnosis 
of ATPD; the remaining developed psychosis. The cumulative incidence (Kaplan-Meier failure function) of 
risk of developing any ICD-10 non-organic psychotic disorder was 16.10% at 1-year (95%CI 14.83-17.47%), 
28.41% at 2-year (95%CI 26.80-30.09%), 33.96% at 3-year (95% CI 32.25-35.75%), 36.85% at 4-year (95%CI 
35.07-38.69%), 40.99% at 5-year (95% CI 39.12-42.92%), 42.58% at 6-year (95%CI 40.67-44.55%), 44.65% 
at 7-year (95% CI 42.66-46.69%), and 46.25% at 8-year (95% CI 44.17-48.37%). The cumulative risk of 
schizophrenia-spectrum disorder at 8-year was 36.14% (95% CI 34.09-38.27%).  
Conclusions: Individuals with ATPD have a very high risk of developing persistent psychotic disorders and 
may benefit from early detection and preventive treatments to improve their outcomes. 
 
Keywords: Acute and transient psychotic disorders; brief psychotic disorders; psychosis risk; schizophrenia, 
prevention, early detection.  
 1. Introduction 
Accounts of brief and acute psychotic episodes [1] are found across different 19th- and 20th-century European 
psychiatric traditions under various terms (for a recent historical review of these construct see [2]). The 
unifying feature across these constructs is of short-lived psychotic symptoms that remit within a relatively 
short period of time. In the modern taxonomy, brief psychotic episodes are classified under "acute and 
transient psychotic disorders" (ATPDs) in ICD-10, and "brief psychotic disorder" (BPD) in DSM-5 [3]. The 
World Health Organization defines ICD-10 ATPDs as psychotic episodes fully remitting within 1 to 3 months, 
with (a) acute onset within 2 weeks; (b) presence of typical syndromes; and (c) presence of associated acute 
stress [4]. Specifically, the ATPDs include six subtypes: acute polymorphic psychotic disorder without 
symptoms of schizophrenia (F23.0, remission within 3 months), acute polymorphic psychotic disorder with 
schizophrenic symptoms (F23.1, remission within 1 month); acute schizophrenia-like psychotic disorder 
(F23.2, remission within 1 month); acute predominantly delusional psychotic disorder (F23.3, remission within 
3 months); and ‘other’ (F23.8) and ‘unspecified’ (F23.9) acute and transient psychotic disorders. Complete 
remission within 1 or 3 months sets the ATPDs with schizophrenic symptoms apart from schizophrenia (the 
ICD-10 diagnosis of schizophrenia requires at least 1 month’s duration), and the ATPDs with polymorphic or 
delusional features apart from persistent delusional disorder (which lasts longer than 3 months) [3]. Typical 
syndromes differ across the 6 subtypes, from a “polymorphic” rapidly changing and variable state, which 
encompasses emotional turmoil, perplexity, and alterations in motility (F23.0 Acute polymorphic psychotic 
disorder without symptoms of schizophrenia), to subtypes including typical schizophrenic symptoms (F23.1 
Acute polymorphic psychotic disorder with symptoms of schizophrenia; F23.2 Acute schizophrenia-like 
psychotic disorder; F23.3 Other acute predominantly delusional psychotic disorders). Finally, a character may 
be used to indicate whether the first psychotic symptoms emerged within around 2 weeks of one or more events 
that “would be regarded as stressful to most people in similar circumstances, within the culture of the person 
concerned”. Examples of such events include bereavement, marriage, terrorism and unexpected loss of partner 
or job, but should not include long-standing difficulties. 
Conversely, in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), the American 
Psychiatric Association classifies Brief Psychotic Disorders (BPD) as psychotic conditions lasting 1 day or 
more but less than 1 month, with complete remission to the premorbid level of functioning [5]. A diagnostic 
comparison of these two categories has been presented in a recent publication by our group, which is beyond 
the scope of the current study [2]. 
Clinical research interest in ATPDs has grown substantially since their reconceptualization as a state of risk 
for the development of persistent psychotic disorders, approximately two decades ago. Accordingly, the 
Clinical High Risk State for Psychosis (CHR-P) [6] defines individuals who are at risk of developing psychotic 
disorders but not other emerging mental disorders[7, 8]. The CHR-P group includes the Brief and Limited 
Intermittent Psychotic Symptoms (BLIPS) subgroup, which also features short-lived psychotic episodes [9]. 
Compared to ATPDs -which are defined clinically-, the BLIPS are defined through specific psychometric tools 
[10]. There is substantial diagnostic (around 70% of BLIPS cases also meet ATPD criteria [11]) and prognostic 
overlap (with similar levels of psychosis risk over time [2]) between the BLIPS and ATPD categories. 
Reconceptualization of ATPDs within the CHR-P framework has allowed early detection and preventative 
treatments to be offered to some of these patients [12]. 
Whatever the designation, there is converging evidence that brief psychotic episodes are associated with a very 
high risk of developing persistent psychotic disorders, in particular schizophrenia spectrum psychoses. 
Recently, we have meta-analytically estimated that up to half of patients (0.56, 95% CI 0.52-0.60) with an 
ATPD (and BPD) developed another psychotic disorder at an average follow-up of 4.5 years, mostly 
schizophrenia-spectrum disorders (encompassing schizophrenia 0.21 95% CI 0.16-0.25, schizophreniform 
disorder 0.02 95% CI 0.00-0.14, and schizoaffective disorder 0.02 95% CI 0.00-0.06), and less frequently 
affective psychoses 0.12 95% CI 0.07-0.16 [13]. There is less evidence on the longer–term outcomes of ATPD 
individuals. Our meta-analysis uncovered 8 cohort studies reporting on ATPD outcomes at 8 years or longer 
[2]. However, the vast majority of them were based on small samples, ranging from 15 to 54 patients [14-20], 
with inaccurate outcome estimates. Only one study involved a large cohort of ATPD cases [21]. Since the 
long-term results of this study have not been validated externally (outside the Danish psychiatric population), 
their generalizability is currently unclear.  
The current study sought to overcome this limitation in knowledge. Here, we report the longitudinal diagnostic 
outcomes of ATPDs as recorded in a clinical case register that was representative of secondary mental health 
care in the UK. Our first aim was to report and describe the risk of developing persistent psychotic disorders 
in the long term, and then to report the specific risk of developing schizophrenia-spectrum disorders. As 
additional analyses, we also described all diagnostic changes occurring within the follow-up period.  
2. Materials and methods 
2.1. Data source 
Data for this study were automatically extracted from the South London and Maudsley (SLaM) Biomedical 
Research Centre (BRC) Case Register, using the Clinical Record Interactive Search tool (CRIS). Developed 
in 2008, CRIS enables the search of anonymized, real-time information from the electronic health records of 
patients receiving treatment within SLaM [22]. SLaM is a large National Health Service (NHS) Trust providing 
specialist mental health care to a catchment area of 1.3 million residents across four South London boroughs 
(Lambeth, Southwark, Lewisham and Croydon) [22]. Every patient within SLaM has their full personal 
electronic health record, which must be continually updated by SLaM health care professionals as a legal 
requirement [22]. Since CRIS derives direct information from these electronic health records, it is an 
advantageous source of “real-world” and “real-time” information on routine mental health care [23]. CRIS 
was approved by the Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). Access to the 
anonymized data for this study was reviewed, monitored and audited by an Oversight Committee, which carries 
representation from the SLaM Cauldicott Guardian and is chaired by a service user. The CRIS Oversight 
Committee is responsible for ensuring that all research applications comply with ethical and legal guidelines; 
approval for this study was granted on the 4th August 2014. CRIS has been extensively used in over 70 previous 
studies, some of which appeared in high impact factor journals [24-26].  
2.2. Study Population 
All individuals who received a first index diagnosis of ATPD (F23, ICD-10) within SLaM between 1st April 
2006 and 15th June 2017 were initially considered eligible. Consent from patients was not needed as data are 
completely de-identified [22]. We then excluded those with very short-term diagnostic instability, defined as 
diagnostic change occurring within the 3 months immediately following the first index diagnosis of ATPD 
(i.e., in the context of the index episode itself). This was intended as a more robust and complete method of 
measuring diagnoses, excluding provisional highly unstable diagnoses recorded during the period of 
observation. This approach has already been validated in a previous study by our group, published in a high 
impact factor journal [27]. The remaining sample was therefore composed of all patients with a first index 
diagnosis of ATPD, who retained the index diagnosis up to 3 months.  
2.3. Study Measures 
The primary outcome was the long-term (up to 8-year) risk of developing persistent psychotic disorders, 
defined as the onset of the first ICD-10 diagnoses of non-organic psychotic disorders since index diagnosis: 
schizophrenia-spectrum disorders (schizophrenia [F20.x, except F20.4/F20.5], schizoaffective disorder 
[F25.x], delusional disorders [F22.x, F24]); affective-spectrum psychoses (mania with psychotic symptoms 
[F30.2], bipolar affective disorder with psychotic symptoms [F31.2, F31.5], and depression with psychotic 
symptoms [F32.3/F33.3]); psychotic disorders due to psychoactive substance use ([F10-F19].5); unspecified 
non-organic psychoses (F28/F29); and severe mental and behavioural disorders associated with the puerperium 
(puerperal psychosis NOS, F53.1). To better clarify the course of ATPDs, we further provided a descriptive 
analysis of diagnostic changes following the first onset of persistent psychotic disorders. 
Time to persistent psychotic disorders was assessed from the date of first index diagnosis of ATPD, censored 
at 15th June 2017.  
2.4. Statistical Analysis 
This electronic health record-based cohort study was performed according to the REporting of Studies 
Conducted using Observational Routinely-collected health Data statement (RECORD) [28] (eTable 1). 
We described baseline sociodemographic and clinical characteristics of the sample by mean and standard 
deviation (SD) for continuous variables, and by absolute and relative frequencies for categorical variables. 
Sociodemographic and clinical characteristics were then stratified across ATPD subgroups, using one-way 
ANOVA and Tukey post-hoc tests for continuous variables, and chi square tests for categorical variables. For 
descriptive purposes, we also obtained absolute and relative frequencies of every ICD-10 diagnosis of non-
organic psychotic disorders at seven time-points (6, 12, 18, 24, 48, 72, and 96 months).  
The cumulative incidence of non-organic ICD-10 persistent psychotic disorders from ATPD during the follow-
up period was estimated with Kaplan-Meier failure function [29] and Greenwood 95% confidence intervals 
[30]. In a subsequent analysis, we specifically focused on the risk of developing schizophrenia-spectrum 
disorders. Furthermore, we plotted Kaplan–Meier failure curves separately for ATPD subgroups with (F23.1 
and F23.2) or without (F23.0, F23.3, F23.8, and F23.9) schizophrenic symptoms.  
All analyses were conducted in STATA 12 (STATA Corp., TX, USA).  
3. Results 
3.1. Sociodemographic and clinical characteristics of the sample 
Between 1st April 2006 and 15th June 2017, a total of 3286 subjects received a first index primary diagnosis of 
ATPD (F23, ICD-10) within the SLaM NHS Trust. After 3 months, 3074 subjects had retained the index ATPD 
diagnosis. Table 1 depicts the sociodemographic and clinical characteristics of these remaining 3074 patients. 
The mean age was 33.84 years (SD=13.99) and 53% were male (n=1633). Females were older than males, 
mean age 35.32 years (SD=14.72) vs 32.53 years (SD=13.17). The majority were of black ethnicity (n=1353, 
45%), followed by white ethnicity (n=1089, 37%). The most frequent ATPD subtypes were unspecified non-
organic psychoses (F23.8 Other acute and transient psychotic disorders (7.12%), and F23.9 Acute and transient 
psychotic disorders unspecified (63.44%)), together accounting for 71% (n=2169) of the total sample. Other 
subtypes were distributed as follows: F23.1 Acute polymorphic disorder with symptoms of schizophrenia, 
5.82% (n=179); F23.2 Acute schizophrenia-like psychotic disorder, 14.02% (n=431); F.23.0 Acute 
polymorphic disorder without symptoms of schizophrenia, 4.78% (n=147); and F23.3 Other acute 
predominantly delusional psychotic disorders, 4.81% (n=148). ATPDs with recurrent course were relatively 
rare during the follow-up period (n=607, 20%). Approximately one-third of episodes of ATPD lasted more 
than 30 days (n=982, 32%). An acute stress preceding ATPD was present in a small proportion of patients 
(n=34, 1%). Antipsychotics were offered to 65% (n=1998) of patients over the follow-up period.  
*** Table 1 about here *** 
3.2.  Sociodemographic and clinical differences across ATPD subtypes 
Patients with acute predominantly delusional psychotic disorders (F23.3) were comparatively older at ATPD 
onset relative to other ATPD subtypes (mean = 41.74, SD = 16.85) (Table 2). In our sample, ATPD subtypes 
showed overlapping distributions in terms of gender (χ2 = 7.68, p = 0.053) and ethnicity (χ2 = 16.32, p = 
0.177). ATPD subtypes with symptoms of schizophrenia had more frequent recurrent course (χ2 = 33.25, p < 
0.001) and longer duration (χ2 = 19.24, p < 0.001). We did not observe any association between ATPD 
subtypes and associated acute stress (χ2 = 4.78, p = 0.189) (Table 2).  
 *** Table 2 about here *** 
3.3.  Risk of developing persistent psychotic disorders from ATPDs 
The mean follow-up was 1495 days (range: 48-4091). The mean time to psychosis transition was 661 days, 
with the first transition to psychosis observed at 91 days and the last at 2907 days. There were 1191 events, 
with the last onset of persistent psychotic disorders occurring at day 2907 (i.e., at 7.96 years), when 519 patients 
were still at risk. The cumulative incidence (Kaplan-Meier failure function) of risk of developing any ICD-10 
non-organic psychotic disorder was 16.10% at 1-year (95%CI 14.83-17.47%), 28.41% at 2-year (95%CI 
26.80-30.09%), 33.96% at 3-year (95% CI 32.25-35.75%), 36.85% at 4-year (95%CI 35.07-38.69%), 40.99% 
at 5-year (95% CI 39.12-42.92%), 42.58% at 6-year (95%CI 40.67-44.55%), 44.65% at 7-year (95% CI 42.66-
46.69%), and 46.25% at 8-year (95% CI 44.17-48.37%) (Figure 1). 
*** Figure 1 about here *** 
 Figure 2 depicts the diagnostic changes from a first index diagnosis of ATPD to any non-organic psychotic 
disorders -and individual spectra of psychotic disorders- across seven time points (6, 12, 18, 24, 48, 72, and 
96 months). As indicated, at 96 months 875 had received a diagnosis of schizophrenia spectrum disorders (726 
of schizophrenia, 106 of schizoaffective disorders, and 43 of delusional disorders), 145 of affective-spectrum 
psychoses, 22 of psychotic disorders due to psychoactive substance use, 148 of unspecified non-organic 
psychoses, and 1 of severe mental and behavioural disorders associated with the puerperium (F53.1). Figure 
3 represents the cumulative incidence (Kaplan-Meier failure function) of risk of developing any ICD-10 non-
organic persistent psychotic disorder, stratified for the presence or absence of schizophrenic symptoms during 
the index episode of ATPD.  
*** Figure 2 about here *** 
*** Figure 3 about here *** 
3.4 Risk of developing schizophrenia-spectrum disorders from ATPDs 
The mean time to transition to schizophrenia-spectrum disorders was 641 days, with the first transition 
observed at 91 days and the last at 2907 days. There were 875 events, with the last onset of schizophrenia-
spectrum disorders occurring at day 2907 (i.e., at 7.96 years), when 519 patients were still at risk. The 
cumulative incidence (Kaplan-Meier failure function) of risk of developing schizophrenia-spectrum disorders 
was 12.42% at 1-year (95%CI 11.28-13.67%), 21.99% at 2-year (95%CI 20.50-23.58%), 26.27% at 3-year 
(95% CI 24.65-27.99%), 28.93% at 4-year (95%CI 27.21-30.72%), 32.37% at 5-year (95% CI 30.53-34.28%), 
33.35% at 6-year (95%CI 31.48-35.31%), 34.92% at 7-year (95% CI 32.95-36.96%), and 36.14% at 8-year 
(95% CI 34.09-38.27%) (Figure 4). As a supplementary result, we plotted the cumulative incidence (Kaplan-
Meier failure function) of risk of developing schizophrenia-spectrum disorders stratified for the presence or 
absence of schizophrenic symptoms during the index episode of ATPD (eFigure 1). 
*** Figure 4 about here *** 
4. Discussion 
To the best of our knowledge, this is one of the few large-scale studies to report on the long-term outcomes of 
patients affected with ATPDs. A total of 3074 patients receiving a first index diagnosis of ATPD (F23, ICD-
10) within SLaM were included in the study, with a mean follow-up of 1495 days. The overall 8-year risk of 
developing any non-organic ICD-10 persisting psychotic disorders was 46.25% (95% CI 44.17-48.37%). 
Specifically, the risk of developing ICD-10 schizophrenia-spectrum disorders was 36.14% (95% CI 34.09-
38.27%).   
Consistent with our recent meta-analytical estimate of prospective diagnostic stability and instability of brief 
psychotic episodes (ATPD/BPD) [13], the present study suggests that a substantial number of patients with a 
first index diagnosis of ATPD – just under half – would go on to develop persistent psychotic disorders in the 
longer term, with about one third of them developing schizophrenia-spectrum disorders. This result is of 
clinical interest because the ATPD group is distinguished from other types of psychoses, such as schizophrenia 
spectrum psychoses (Schizophrenia, F20; Persistent delusional disorders, F22) on the basis of prototypical 
symptoms, temporal criteria and early remission [4]. In fact, longitudinal studies have indirectly validated the 
initial separation of ATPD from frank schizophrenic psychoses. In our recent meta-analysis, we found that 
approximately half of ATPD patients were still in remission and free from any psychotic relapse (46%) at more 
than 3-years. In contrast, only a tiny minority of patients receiving an initial diagnosis of first-episode 
schizophrenia, and who have experienced a clinical remission (such as for ATPDs), do not relapse (16%) [2].  
In our study, we found a mean time to any non-organic psychotic disorders from ATPD of 1.8 years. We found 
that patients presenting with schizophrenic symptoms during the index episode of ATPD had a slightly higher 
risk of developing persistent psychotic disorders, and specifically schizophrenia-spectrum psychoses. These 
results could provide support to the announced diagnostic revision planned in the upcoming ICD manual (ICD-
11), where only the ATPD polymorphic subtype without symptoms of schizophrenia (F23.0) will be retained 
in the ATPD rubric, while the ATPD subtypes with symptoms of schizophrenia (F23.1 and F23.2) will be 
collapsed into “unspecified primary psychotic disorders” if lasting less than 4 weeks, and the delusional 
subtype (F23.3) will be moved to the new category of delusional disorders [31]. Nonetheless, our results are 
to be interpreted cautiously, as the clinical significance of the slight difference we observed between the two 
groups requires further clarification. It is also worth noting that the majority of our sample (71%) received a 
diagnosis of the residual subtypes - other (F23.8) and unspecified (F23.9) acute and transient psychotic 
disorders - which suggests that, as previously indicated by others [32], the typical ATPD syndromes - 
polymorphic, schizophrenia-like, or predominantly delusional – are of difficult applicability in common 
clinical settings. 
Our study may have some clinical implications. We confirmed that patients receiving an ATPD diagnosis have 
a very high risk of developing persistent psychotic disorders, in particular schizophrenia spectrum psychoses. 
Despite their level of psychosis risk being comparable to that of other individuals under the care of CHR-P 
services, ATPD patients are not systematically detected and signposted for the specialized preventative 
assessment and treatment which is offered to CHR-P individuals. In a recent observational study conducted in 
our NHS Trust, we observed that the vast majority of individuals receiving an ATPD diagnosis were not 
referred to the local CHR-P service [27]. This occurred in spite of an extensive outreach campaign for the 
detection of individuals at risk of psychosis being promoted and fully implemented by the local CHR-P service. 
Astonishingly, CHR-P individuals accounted for only 5% of first-episode psychosis cases, and ATPDs for 
26% of them. It is therefore apparent that preventing the onset of psychotic disorders in ATPD patients has the 
potential to improve outcomes of first-episode psychosis to a greater extent than focusing on CHR-P 
individuals only. The additional problem is that currently, there are no specific treatment guidelines for ATPD 
patients. For example, according to the NICE clinical guideline CG178 “psychosis and schizophrenia in adults: 
prevention and management” [33], ATPD patients should be offered oral antipsychotic medication in 
conjunction with psychological therapies. Such a recommendation conflicts with the fact that at the time of 
their diagnosis, all of these patients would be -by definition- free from any psychotic symptoms. There is no 
indication as to for how long to continue such a hypothetical antipsychotic treatment, and no clear rationale. 
For example, no consideration is given to the risk of exposing false positives (about half) to unnecessary 
antipsychotic treatment. There are also no antipsychotic molecules formally licensed for ATPDs and very few 
trials have been conducted in these patients. Some evidence suggests that excessive prescription of 
antipsychotics may actually increase the risk of developing persistent psychotic disorders (such as 
schizophrenia) in these patients [34]. Although it is argued that first-episode services may take care of these 
individuals as for other psychotic diagnoses, there are no robust data showing that ATPD patients remain under 
the care of these services [35]. Rather, in a time of scarce resources in the NHS, it is more likely that these 
individuals would be discharged back to their general practitioners soon after their symptoms have resolved. 
Overall, these considerations expose a major window of unmet need. There is also a clear window of missed 
preventative opportunities. The available alternative could be to detect and signpost ATPD patients for a 
psychosis risk assessment, such as those performed with validated psychometric tools in CHR-P clinics. For 
those testing positive, clinical monitoring along with recommended CHR-P preventative interventions could 
be offered. Such an approach holds the potential to address most of the above limitations, offering an 
individualized package of care for those ATPD cases most at risk of developing persistent psychotic disorders. 
Clearly, the first barrier towards this would be our ability -or lack thereof- to detect most of the ATPD patients 
diagnosed by clinicians [12]. Extensive screening is not sustainable on a financial and logistical scale. 
However, a recent individualized clinically based risk calculator for the transdiagnostic detection of individuals 
at risk of developing psychosis (including ATPD cases) has been validated for this purpose [27]. Further 
research is ongoing and it is hoped that in the near future, we will be better able to detect patients with ATPDs 
accessing secondary mental health care in order to offer preventative interventions and improve their long-
term outcomes [12]. 
The present study has some limitations, particularly those inherent to the use of electronic health records. We 
employed the diagnoses recorded in CRIS by clinicians as part of standard clinical practice. Although very 
good in terms of ecological validity (i.e., they represent real-world clinical practice), they have not been 
validated with research-based criteria. However, data recorded in electronic health registers has previously 
been shown to have good reliability in the realm of psychotic categories [36-38]. Moreover, we did not 
systematically assess patients during the follow-up period, relying instead on data from routine clinical care, 
which is influenced by a complex interaction of patient and service-related factors. It is possible that patients 
were discharged from mental health services during the follow-up period because of symptomatic 
improvement, disengagement from mental health services, moving outside the SLaM catchment area, or other 
reasons. However, as previously noted in at-risk samples [39], the use of structured diagnostic interviews can 
lead to selection of patient subsamples and introduce additional biases. Recently we have pragmatically 
validated our approach, by showing that psychotic outcomes that were estimated through our electronic case 
register [26] were consistent with those reported by other sites [10, 40]. 
 
5. Conclusions 
This study confirmed that approximately half of patients with a first index diagnosis of ATPD will develop a 
persistent non-organic psychotic disorder over 8-year follow-up. In particular, 36% of patients with a first 
ATPD presentation will develop a disorder in the schizophrenia spectrum. ATPDs share diagnostic and 
prognostic commonalities with other risk syndromes that are currently employed to detect individuals at risk 
and prevent psychosis. Patients with a first ATPD episode should be referred for a psychosis risk assessment 
and signposted for preventive interventions.  
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Table 1. Sociodemographic and clinical characteristics of patients with a first index diagnosis of ATPD. 
 
Sociodemographic characteristics     
  N Mean SD 
Age   3072 33.84 13.99 
  N Count % 
Gender  3074   
 Males  1633 53.12 
 Females  1441 46.88 
Ethnicity  2981   
 White  1089 36.53 
 Black  1353 45.39 
 Asian  232 7.78 
 Mixed  70 2.35 
 Other  237 7.95 
Clinical characteristics     
ATPD subtype  3074   
 F23.0  147 4.78 
 F23.1  179 5.82 
 F23.2  431 14.02 
 F23.3  148 4.81 
 F23.8 or F23.9  2169 70.56 
ATPD course  3074   
 Episodic  2467 80.25 
 Recurrent  607 19.75 
Non-rapidly remitting symptoms  3074   
 <30 days  2092 68.05 
 >30 days  982 31.95 
Associated Acute stress  3074   
 No  3040 98.89 
 Yes  34 1.11 
Antipsychotics  3074   
 No  1076 35 
 Yes  1998 65 
 
 
  
Table 2. Sociodemographic and clinical differences across ATPD subtypes 
 
 F23.0 F23.1 or F23.2 F23.3 F23.8 or F23.9  
 Mean SD Mean SD Mean SD Mean SD F p 
Age 34.32 13.44 32.20 13.02 41.74 16.85 33.73 13.90 18.99 <0.001 
 Count % Count % Count % Count % χ2 P 
Gender         7.68 0.053 
Males 62 3.80 331 20.27 77 4.72 1163 71.22   
Females 85 5.90 279 19.36 71 4.93 1006 69.81   
Ethnicity         16.32 0.177 
White 48 4.41 210 19.28 58 5.33 773 70.98   
Black 62 4.58 288 21.29 51 3.77 952 70.36   
Asian 14 6.03 39 16.81 15 6.47 164 70.69   
Mixed 3 4.29 6 8.57 4 5.71 57 81.43   
Other 14 5.91 49 20.68 14 5.91 160 67.51   
ATPD course         33.25 <0.001 
Episodic 122 4.95 439 17.79 124 5.03 1782 72.23   
Recurrent 25 4.12 171 28.17 24 3.95 387 63.76   
Non-rapidly 
remitting 
symptoms 
        19.24 <0.001 
< 30 days 87 4.16 380 18.16 104 4.97 1521 72.71   
> 30 days 60 6.11 230 23.42 44 4.48 648 65.99   
Associated Acute 
stress 
        4.78 0.189 
No 146 4.80 599 19.70 148 4.87 2147 70.63   
Yes 1 2.94 11 32.35 0 0 22 64.71   
Figure captions  
 
Figure 1. Cumulative incidence (Kaplan-Meier failure function) of risk of developing non-organic persistent 
psychotic disorders in patients with an index diagnosis of ATPD (n=3074). There were 2431 subject at risk at 
1-year, 1924 subjects at risk at 2-year, 1598 subjects at risk at 3-year, 1340 subjects at risk at 4-year, 1066 
subjects at risk at 5-year, 862 subjects at risk at 6-year, 655 subjects at risk at 7-year, and 515 subjects at risk 
at 8-year follow-up.  
 
Figure 2. Prospective diagnostic changes from an index diagnosis of ATPD to other spectra of psychotic 
disorders across seven time points (6, 12, 18, 24, 48, 72, and 96 months).  
* 2 patients, at 48 and 96 months, received the diagnosis of severe mental and behavioural disorders associated 
with the puerperium [Puerperal psychosis NOS] (F53.1).  
 
Figure 3. Cumulative incidence (Kaplan-Meier failure function) of risk of developing non-organic persistent 
psychotic disorders stratified for the presence of schizophrenic symptoms during the index ATPD episode. 
Figure 4. Cumulative incidence (Kaplan-Meier failure function) of risk of developing schizophrenia-spectrum 
disorders in patients with a first index diagnosis of ATPD (n=3074).   
 
